Which medications in the drug class HIV, Entry Inhibitors are used in the treatment of HIV Infection and AIDS?

Updated: Jul 27, 2020
  • Author: Shelley A Gilroy, MD, FACP, FIDSA; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print

HIV, Entry Inhibitors

Approval of ibalizumab was based on the MB-301 phase 3 trial. MB-301 was a single-arm, 24-week study of ibalizumab plus optimized background regimen (OBR) in treatment-experienced patients infected with multidrug-resistant HIV-1 virus.

The following study results were observed at 24 weeks: [165]

Among study participants, 43% achieved viral suppression < 50 copies/mL, and half achieved < 200 copies/mL.

While 60% of those with a baseline CD4 count of > 50 cells/µL achieved undetectable viral load, this fell to < 20% in those with lower CD4 counts.

Among participants, 55% had at least a 1 log decrease and 48% had at least a 2 log decrease in HIV RNA; the average reduction from baseline was 1.6 log.

The overall average CD4 cell gain was 48 cells/µL, but this differed according to baseline level; people who started with at least 50 cells/µL saw a mean gain of about 75 cells/µL, while those with lower baseline levels gained an average of 9 cells/µL.

Ibalizumab (Ibalizumab-uiyk, Trogarzo)

CD4-directed post-attachment inhibitor that prevents viral entry and fusion within the CD4 cell. Ibalizumab does not inhibit HIV gp120 attachment to CD4; however, its postbinding conformational effects block the gp120-CD4 complex from interacting with CCR5 or CXCR4 and thus prevents viral entry and fusion while preserving normal immunological function. It is indicated for HIV-1 infection in heavily treated adults with multidrug-resistance. It is used in combination with the patient’s current ART regimen.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!